Showing results (231-240 of 252) with videos related to
Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countriesChi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Zijun Y Xu-Monette, Xin Cao, et al.Cancer Immunology Research|February 13, 2019
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCLZiju Y Xu-Monette, Min Xiao, Qingyan Au, et al.Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.Leukemia|August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaY Xia, Z Y Xu-Monette, A Tzankov, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2015
Hodgkin lymphoma, version 2.2015Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.Blood|October 26, 2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphomaZijun Y Xu-Monette, Ling Li, John C Byrd, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.Pageof 26